08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Risk-benefit litmus test

Beloranib's role in two deaths with concurrent thrombotic events will be difficult to elucidate in a condition whose biology is not well understood. However, if Zafgen Inc. can characterize and mitigate the risk through an...
07:00 , Sep 22, 2014 |  BioCentury  |  Strategy

Weighing in on obesity

Contrave naltrexone/bupropion will be the first new obesity drug launched in the past two years to have the full weight of a large pharma partner with an established commercial footprint in the cardiometabolic space behind...
07:00 , Jul 22, 2013 |  BioCentury  |  Product Development

Biggest loser

Preliminary Phase II data for Zafgen Inc. 's beloranib provide the first clinical support for the company's hypothesis that the compound could compete with bariatric surgery to treat obesity. While the data cover only a...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

OxiGene, Boston Medical Center deal

The center, affiliated with Boston University Medical Center, will collaborate with the company under a sponsored research agreement to study OXGN's Neu-Sensamide and Oxi-104 as chemosensitizers of cordycepin (3'-deoxyadenosin). OXGN has an option to acquire...
07:00 , Aug 6, 2012 |  BioCentury  |  Strategy

Paying to lose

Now that FDA has approved two obesity drugs, the next challenge is getting payers on board, as only about 30% of prescriptions for weight loss drugs are currently reimbursed. The latest to cross the finish...
08:00 , Dec 13, 2010 |  BioCentury  |  Regulation

It Pays to Weight

Sometimes going last can be a good thing. After two other obesity candidates failed to win the support of FDA advisory committees and Meridia sibutramine was taken off the market in October, Orexigen Therapeutics Inc....
07:00 , Jul 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Glomerulonephritis Anti-phospholipase A2 receptor 1 (PLA2R1) Autoantibodies to PLA2R1 could be diagnostic markers for idiopathic membranous glomerulonephritis. Anti-PLA2R1 was detected in the sera of...
07:00 , Apr 20, 2009 |  BioCentury  |  Product Development

Weight and See

There are now three obesity compounds in late-stage development with positive Phase III data, which means the number of drugs available for the indication could double over the next few years. But at least some...
08:00 , Dec 8, 2008 |  BioCentury  |  Strategy

Ranexa's new script

While CV Therapeutics Inc. got everything it asked FDA for in its expanded label for Ranexa ranolazine, cardiologists predict doctors will need to see the drug's newly approved benefits for themselves before they begin to...
08:00 , Dec 9, 2002 |  BC Week In Review  |  Company News

Centagenetix, Boston University, Boston Medical Center deal

The entities partnered to conduct research on the diseases of aging. Under the deal, each party will contribute genetic samples collected from centenarians for disease correlation and diagnostic relevance. Centagenix will have exclusive commercial rights...